Welcome to our dedicated page for Prestige Consmr Healthcare SEC filings (Ticker: PBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From Clear Eyes drops that dominate eye-care aisles to Summer’s Eve feminine hygiene solutions, Prestige Consumer Healthcare Inc. lives at the center of the OTC medicine cabinet. Shifts in shelf velocity or raw-material pricing show up quickly inside a Prestige Consumer Healthcare quarterly earnings report 10-Q filing, while sudden recalls surface in a Prestige Consumer Healthcare 8-K material events explained the same day. Investors scanning for early signals need more than EDGAR links—they need context that ties brand performance to cash flow.
Stock Titan delivers that context. Our AI creates card-style highlights that make Prestige Consumer Healthcare SEC filings explained simply, turning the dense Prestige Consumer Healthcare annual report 10-K simplified into an interactive brief. Alerts flag every Prestige Consumer Healthcare Form 4 insider transactions real-time, so tracking Prestige Consumer Healthcare executive stock transactions Form 4 becomes effortless. For governance insights, the full Prestige Consumer Healthcare proxy statement executive compensation is paired with plain-language notes. And if you prefer deeper dives, understanding Prestige Consumer Healthcare SEC documents with AI means clickable footnotes, searchable tables, and instant ratio calculations.
Practical use cases are built in. Receive push notices when a director buys powder-brand shares—Prestige Consumer Healthcare insider trading Form 4 transactions delivered within minutes. Compare segment revenue trendlines across filings to power your Prestige Consumer Healthcare earnings report filing analysis, or export cash-conversion figures to Excel. Real-time coverage spans every form—10-Q, 10-K, 8-K, S-8—updated the moment they hit EDGAR. Skip page flipping and focus on decisions; our expert commentary flags supply-chain risk language, goodwill impairment tests, and marketing spend changes so that insights arrive before the market reacts.
Prestige Consumer Healthcare (PBH) reported Q2 results. Total revenues were $274.1 million for the three months ended September 30, 2025, down 3.4% year over year. Net income was $42.2 million and diluted EPS was $0.86. Gross margin was 55.3%, slightly lower than 55.5% a year ago as International margins softened. Operating income was $79.7 million, while the effective tax rate rose to 38.9% primarily due to a new state tax presence.
For the six months, revenues were $523.6 million (down 5.0%) and operating cash flow reached $136.5 million. The company repurchased $109.8 million of stock at an average price of $70.34, ending with $119.1 million in cash. Long‑term debt remained $1.0 billion, with $190.0 million of unused capacity on the 2012 ABL Revolver. North American sales declined on Eye & Ear Care shortages, while Gastrointestinal grew; International revenue was roughly flat with mixed category performance.
Prestige Consumer Healthcare (PBH) announced financial results for the fiscal quarter and six months ended September 30, 2025. The company furnished a press release detailing the results as Exhibit 99.1 and an investor presentation as Exhibit 99.2.
Management began using the investor presentation on November 6, 2025 and may use it during the fiscal year ending March 31, 2026. The materials in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 are furnished, not filed, and are not subject to Section 18 liabilities unless specifically stated otherwise.
Schedule 13G/A disclosure by Ariel Investments, LLC reports beneficial ownership of 2,202,327 shares of Prestige Consumer Healthcare common stock, representing 4.5% of the class. Ariel states it has sole voting power over 1,950,287 shares and sole dispositive power over 2,202,327 shares. The filing certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Ariel notes its adviser clients have rights to dividends or sale proceeds on these securities and that no client has an economic interest exceeding 5%.
FAQ
What is the current stock price of Prestige Consmr Healthcare (PBH)?
What is the market cap of Prestige Consmr Healthcare (PBH)?
